​

BioNTech SE (BNTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BNTX Stock Forecast

BioNTech SE (BNTX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $130.80, with a high of $145.00 and a low of $121.00. This represents a 32.44% increase from the last price of $98.76.

$80 $93 $106 $119 $132 $145 High: $145 Avg: $130.8 Low: $121 Last Closed Price: $98.76

BNTX Stock Rating

BioNTech SE stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (80.95%), 4 Hold (19.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 4 17 0 Strong Sell Sell Hold Buy Strong Buy

BNTX Price Target Upside V Benchmarks

TypeNameUpside
StockBioNTech SE32.44%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts1115
Avg Price Target$145.00$145.00$121.27
Last Closing Price$98.76$98.76$98.76
Upside/Downside46.82%46.82%22.79%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 255134--22
Mar, 255125--22
Feb, 254125--21
Jan, 254125--21
Dec, 245115--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 01, 2025H.C. Wainwright$145.00$90.2960.59%46.82%
Nov 19, 2024Cory KasimovEvercore ISI$125.00$80.8054.70%26.57%
Nov 13, 2024Daina GrayboschLeerink Partners$121.00$80.8049.75%22.52%
Nov 08, 2024Chris ShibutaniGoldman Sachs$137.00$110.6623.80%38.72%
Nov 04, 2024Etzer DaroutBMO Capital$126.00$108.9715.63%27.58%
Sep 23, 2024Terence FlynnMorgan Stanley$145.00$113.0528.26%46.82%
Sep 17, 2024Akash TewariJefferies$150.00$123.9721.00%51.88%
Sep 16, 2024Tazeen AhmadBank of America Securities$150.00$123.4021.56%51.88%
Sep 13, 2024Akash TewariJefferies$96.00$105.00-8.57%-2.79%
Aug 06, 2024Emmanuel PapadakisDeutsche Bank$95.00$79.5019.50%-3.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 19, 2024Evercore ISIOutperformupgrade
Nov 13, 2024Leerink PartnersOutperformOutperformhold
Nov 08, 2024Goldman SachsBuyBuyupgrade
Oct 21, 2024Cowen & Co.HoldHoldhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 07, 2024UBSBuyBuyhold
Sep 23, 2024Morgan StanleyEqual-WeightOverweightupgrade
Sep 19, 2024Deutsche BankBuyBuyhold
Sep 18, 2024UBSNeutralNeutralhold
Sep 16, 2024Cowen & Co.HoldHoldhold

Financial Forecast

EPS Forecast

$-10 $2 $14 $26 $38 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.06$42.18$38.78------
Avg Forecast$-1.59$36.10$34.97$4.31$-3.16$-3.35$-3.47$-3.25$-2.46
High Forecast$-1.05$48.32$46.41$4.81$-1.30$-0.06$-0.33$0.74$-1.59
Low Forecast$-2.12$23.91$25.17$3.93$-4.51$-6.55$-8.43$-9.21$-3.52
Surprise %-103.77%16.84%10.90%------

Revenue Forecast

$0 $5B $10B $15B $20B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$482.32M$18.98B$17.31B$3.82B-----
Avg Forecast$450.03M$19.46B$17.85B$4.62B$2.74B$2.67B$2.67B$2.88B$3.64B
High Forecast$567.18M$24.53B$22.33B$5.53B$2.84B$3.59B$2.77B$2.96B$4.86B
Low Forecast$333.12M$14.41B$14.00B$4.37B$2.57B$1.99B$2.58B$2.80B$2.65B
Surprise %7.18%-2.50%-3.00%-17.39%-----

Net Income Forecast

$-5B $-1B $3B $7B $11B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.20M$10.29B$9.43B$930.30M-----
Avg Forecast$-384.83M$8.76B$8.49B$1.06B$-418.00M$-827.47M$-822.38M$-750.84M$-595.90M
High Forecast$-254.87M$11.73B$11.26B$1.17B$-315.60M$-13.70M$-80.17M$180.75M$-385.97M
Low Forecast$-515.07M$5.80B$6.11B$953.15M$-1.10B$-1.59B$-2.05B$-2.23B$-855.45M
Surprise %-103.95%17.46%11.15%-12.31%-----

BNTX Forecast FAQ

Is BioNTech SE stock a buy?

BioNTech SE stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioNTech SE is a favorable investment for most analysts.

What is BioNTech SE's price target?

BioNTech SE's price target, set by 21 Wall Street analysts, averages $130.8 over the next 12 months. The price target range spans from $121 at the low end to $145 at the high end, suggesting a potential 32.44% change from the previous closing price of $98.76.

How does BioNTech SE stock forecast compare to its benchmarks?

BioNTech SE's stock forecast shows a 32.44% upside, underperforming the average forecast for the healthcare stocks sector (35.94%) and underperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for BioNTech SE over the past three months?

  • April 2025: 22.73% Strong Buy, 59.09% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 22.73% Strong Buy, 54.55% Buy, 22.73% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 19.05% Strong Buy, 57.14% Buy, 23.81% Hold, 0% Sell, 0% Strong Sell.

What is BioNTech SE’s EPS forecast?

BioNTech SE's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.16, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-3.35 in 2025, $-3.47 in 2026, $-3.25 in 2027, and $-2.46 in 2028.

What is BioNTech SE’s revenue forecast?

BioNTech SE's average annual revenue forecast for its fiscal year ending in December 2024 is $2.74B, reflecting a -28.21% decrease from the reported $3.82B in 2023. The forecast for 2025 is $2.67B, followed by $2.67B for 2026, $2.88B for 2027, and $3.64B for 2028.

What is BioNTech SE’s net income forecast?

BioNTech SE's net income forecast for the fiscal year ending in December 2024 stands at $-418M, representing a -144.93% decrease from the reported $930.3M in 2023. Projections indicate $-827M in 2025, $-822M in 2026, $-751M in 2027, and $-596M in 2028.